RecruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Eligible age
18–65 yrs
Accepts
All genders
Locations
18 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Sponsor: Vertex Pharmaceuticals Incorporated
Where it's recruiting
Alabama
Alabaster · Birmingham
California
Los Angeles · San Francisco
Connecticut
Middlebury · New Haven
Florida
Jacksonville
Georgia
Atlanta · Columbus
Illinois
Chicago
Iowa
Iowa City
Kansas
Kansas City
Maryland
Baltimore
Massachusetts
Boston
Minnesota
Minneapolis · Rochester
Nevada
Las Vegas
Source: ClinicalTrials.gov · NCT07161037 · last updated 2026-06-15